scispace - formally typeset
C

Christophe Pannecouque

Researcher at Rega Institute for Medical Research

Publications -  606
Citations -  16959

Christophe Pannecouque is an academic researcher from Rega Institute for Medical Research. The author has contributed to research in topics: Reverse transcriptase & Nucleoside Reverse Transcriptase Inhibitor. The author has an hindex of 61, co-authored 564 publications receiving 14677 citations. Previous affiliations of Christophe Pannecouque include Purdue University & The Catholic University of America.

Papers
More filters
Journal ArticleDOI

Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later

TL;DR: The long-standing and intensive use of the MTT method has taught users of the limitations and the unexpected advantages of the MT-4/MTT assay, and this method can be extended to antiviral testing of compounds against other cyto-destructive viruses.
Journal ArticleDOI

Synthesis and antiviral activity of new pyrazole and thiazole derivatives

TL;DR: The antiviral activity for such novel compounds against a broad panel of viruses in different cell cultures revealed that N-acetyl 4,5-dihydropyrazole 7 was the only active one at subtoxic concentrations against vaccinia virus (Lederle strain) in HEL cell cultures with a 50% effective concentration (EC(50) value of 7 microg/ml.
Journal Article

Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: Implications for treatment and postexposure prophylaxis

TL;DR: Findings support the use of NRTIs, tenofovir, but not NN RTIs, for treating HIV-2-infected persons or for prophylaxis against HIV- 2 and SIV, and show co-receptor antagonists such as AMD3100 show promising anti-HIV-2 therapeutic modalities.
Journal ArticleDOI

Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle.

TL;DR: The antiviral activity of plant lectins with specificity for different glycan structures against the severe acute respiratory syndrome coronavirus (SARS-CoV) and the feline infectious peritonitis virus (FIPV) in vitro is described.
Journal ArticleDOI

Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends

TL;DR: The development of phosphate ester-based prodrugs as a means to improve the aqueous solubility of HIV inhibitors, the introduction of the substrate envelope hypothesis as a new approach for overcoming HIV drug resistance, and future directions for research are discussed.